Myriad Genetics
MYGNNASDAQMyriad Genetics specializes in molecular diagnostic tests, particularly genetic testing for hereditary cancers, tumor profiling, and prenatal screening. Their core technology involves analyzing DNA to identify mutations that increase disease risk or guide treatment decisions.
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-09-09. Published by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.
text updated 2026-09-09 · archived: kept for reference, not maintained · where each field comes from
Key figures from SEC filings
Upcoming catalysts
No upcoming catalyst for Myriad Genetics has been confirmed against a primary source. Rather than estimate one, this section is left empty — check the company's investor relations page and ClinicalTrials.gov directly.
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| Genetic Testing for All Breast Cancer Patients (GET FACTS) | Breast Cancer | Approved | Completed | ▼ |
| Olaparib Companion Diagnostic | Metastatic Castration-Resistant Prostate Cancer | Preclinical | Not disclosed | ▼ |
| Myriad HRD Test | Ovarian Cancer | Phase 3 | Not disclosed | ▼ |
| SHARON Trial | Metastatic Pancreatic and Breast Cancer | Phase 1 | 2026 | ▼ |
| Combined Carrier and Hereditary Cancer Screening | Hereditary Cancer Syndromes | Approved | Recruiting | ▼ |
| SKB264 Companion Diagnostic | Solid Tumors | Phase 2 | Not disclosed | ▼ |
| BRACAnalysis CDx for Triple Negative Breast Cancer | Triple Negative Breast Cancer | Phase 2 | Completed | ▼ |
| Genetic Evaluation of Men (GEM) | Prostate Cancer | Approved | Terminated | ▼ |
| BGB-290 Companion Diagnostic | Solid Tumors | Phase 1 | Completed | ▼ |
| Myriad HRD Test for Non-gBRCAm Ovarian Cancer | Ovarian Cancer | Phase 3 | Completed | ▼ |
What does Myriad Genetics do?
Myriad Genetics is a company that makes tests to look at your DNA. They are best known for tests that tell you if you have a high risk of getting certain cancers, like breast or ovarian cancer, because you inherited a bad gene. They also make tests that help doctors pick the right medicine for cancer patients by looking at the tumor's DNA. For example, their test can show if a patient has a BRCA mutation, which means they might benefit from a drug called a PARP inhibitor. Myriad is not a typical biotech that makes drugs; instead, they are a diagnostic company. They make money by selling these tests to hospitals and labs. The company is trying to grow by making new tests for more types of cancer and by partnering with drug companies to make sure their tests are used with new treatments. For an investor, the key is to watch how many tests they sell and whether insurance companies pay for them. If they can sell more tests and get good reimbursement, they can be profitable. But they face competition from other genetic testing companies, and sometimes insurance companies don't want to pay for these tests, which can hurt sales.
What to watch
Quarterly test volumes and revenue growth
Reimbursement coverage decisions from Medicare and private insurers
FDA approvals for new companion diagnostics
Partnership announcements with pharmaceutical companies
Competitive pricing actions from rivals like Invitae and Natera
Investment thesis
Moderate RiskBull case
Myriad Genetics is a leader in hereditary cancer testing with a strong brand and extensive genetic database. The company is expanding into new areas like tumor profiling and prenatal screening, driving revenue growth. Recent partnerships with pharmaceutical companies for companion diagnostics could create recurring revenue streams. With a solid cash position and improving operational efficiency, Myriad is well-positioned to benefit from the growing adoption of genetic testing in precision medicine. The company's focus on high-value tests and reimbursement coverage could lead to margin expansion and profitability.
Bear case
Myriad faces intense competition from larger players like Invitae and Natera, which may undercut pricing. Reimbursement pressures and regulatory changes could impact test volumes. The company's reliance on a few key products makes it vulnerable to shifts in clinical guidelines. Additionally, the termination of the GEM trial and mixed trial results raise questions about pipeline execution. High R&D costs and a history of revenue volatility may deter investors. If Myriad fails to innovate or differentiate, it could lose market share and see declining revenue.
Risk factors
Reimbursement cuts for genetic tests could reduce revenue.
Competition from larger diagnostics companies may erode market share.
Dependence on a few key products makes revenue vulnerable to guideline changes.
Regulatory hurdles for companion diagnostics could delay product launches.
Termination of the GEM trial may indicate challenges in research execution.
Comparable companies
Sponsored
Get premium MYGN analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you